Calamos Advisors
SRPT icon

Calamos Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Calamos Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,016
Closed -$2.07M – 1058
2023
Q1 		$2.07M Buy
15,016
+4,302
+40% +$558K 0.01% 740
2022
Q4 		$1.39M Buy
10,714
+1,724
+19% +$200K 0.01% 832
2022
Q3 		$994K Buy
+8,990
New +$906K ﹤0.01% 945

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calamos Advisors's SRPT Position: Q2 2023 in Review

Calamos Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 15,016 shares — an estimated $2.07M sold.

Calamos Advisors first reported a position in SRPT in Q3 2022 and held it in 3 quarters. The position peaked at $2.07M in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Calamos Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Calamos Advisors sold 15,016 Sarepta Therapeutics shares in Q2 2023, an estimated $2.07M.
  • Calamos Advisors first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 3 quarters.
  • Calamos Advisors's Sarepta Therapeutics position peaked at $2.07M in Q1 2023.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Calamos Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.